Status: Not yet recruiting
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
Participants needed: 41
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUpdated: Sep 23, 2026Locations: 1
Eligibility criteria
Eligible patients include patients with malignancy treated with ICI, who have be... [+14]
History of grade 4 irAE (attributed to ICI per CTCAE v6.0) [+12]